20,304 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Bought by Virtu Financial LLC

Virtu Financial LLC purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 20,304 shares of the company’s stock, valued at approximately $417,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. State Street Corp boosted its position in shares of Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after acquiring an additional 780,754 shares in the last quarter. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 5.7% during the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after purchasing an additional 659,651 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Intellia Therapeutics by 19.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after purchasing an additional 371,189 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Intellia Therapeutics by 33.5% in the 3rd quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company’s stock worth $21,118,000 after buying an additional 257,700 shares in the last quarter. Finally, Sphera Funds Management LTD. lifted its position in shares of Intellia Therapeutics by 108.8% during the 3rd quarter. Sphera Funds Management LTD. now owns 291,080 shares of the company’s stock worth $5,982,000 after buying an additional 151,661 shares during the period. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Down 4.9 %

NTLA stock opened at $12.90 on Monday. The business has a fifty day moving average of $16.13 and a 200-day moving average of $20.60. The company has a market cap of $1.31 billion, a P/E ratio of -2.37 and a beta of 1.76. Intellia Therapeutics, Inc. has a twelve month low of $12.47 and a twelve month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. During the same quarter in the previous year, the company posted ($1.38) earnings per share. The business’s revenue for the quarter was down 24.1% on a year-over-year basis. As a group, equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current fiscal year.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at $893,698.12. The trade was a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

NTLA has been the topic of a number of analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $90.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Royal Bank of Canada reiterated an “outperform” rating and set a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday, September 19th. The Goldman Sachs Group reduced their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Stifel Nicolaus dropped their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. Finally, StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $54.94.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.